Given the synergistic potency of combining PD-1 blockade with NeoAg peptide vaccination and the ability of the Mut_48 peptide to induce both CD4+ and CD8+ T cell responses against the SCC VII tumor, we examined whether these could be combined to treat large established tumors. The gene discussed is CD8A; the disease is neoplasm.